Applies to most patients with one or two positive sentinel lymph nodes ...

Neoadjuvant chemotherapy (NAC) is one of the standard-of-care therapies for breast cancer (BC) with axillary lymph node (ALN) metastases. However, the response to this therapy varies depending on the ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Thousands of women could now be spared one of the most debilitating side-effects of breast cancer treatment - lifelong ...

The management of axillary lymph nodes in breast cancer is continually evolving. Recent data now support omitting axillary lymph node dissection (ALND) in most patients with metastases in up to two ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

It is possible to leave most of the lymph nodes in the armpit, even if one or two of them have metastases larger than two millimeters. This is shown in a trial enrolling women from five countries. The ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment. Targeted axillary dissection is used for ...